Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Dean F. Bajorin, Andrea Necchi et al.|New England Journal of Medicine|2017Cited by 3.4k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial CarcinomaThomas Powles, Noah M. Hahn, Peter H. O’Donnell et al.|JAMA Oncology|2017Cited by 846
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell CarcinomaRana R. McKay, Toni K. Choueiri, Dominick Bossé et al.|Cancer Immunology Research|2018Cited by 136
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancerChanghwan Sung, Sook Ryun Park, Jinhyeon An et al.|Nature Cancer|2023Cited by 46
Clinical Outcomes of Small Cell Carcinoma of the Genitourinary Tract and the Prognostic Significance of the Tumor Immune MicroenvironmentJaewon Hyung, Jae‐Lyun Lee|Cancer Research and Treatment|2023Cited by 0